drugset / Trial / NCT03145831

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

NCT03145831

Phase 3 Terminated 21 enrolled Versartis Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is a multi-center, open-label safety study assessing long-term somavaratan administration.

Timeline

Start
2017-03-31
Primary completion
2017-11-30
Completion
2017-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Somavaratan Protein / enzyme biologic 3.5 mg/kg Subcutaneous

Indications